Overview
- Lormalzi, which received CDSCO marketing authorisation, launched in India on Wednesday with each 350 mg vial priced at Rs 91,688.
- The once‑monthly infusion targets amyloid plaques and is used for about 18 months in early Alzheimer’s, with diagnosis and amyloid confirmation required.
- Use requires MRI safety checks and often APOE4 genotyping, services that are scarce and costly in many areas even as India counts roughly 8.8 million people with dementia.
- Clinical trials showed modest slowing of decline but also risks, including brain swelling in about 24% and brain bleeds in 19.7%, with three treatment‑related deaths reported.
- A recent Cochrane review judged class‑wide benefits as absent or trivial, a conclusion Lilly disputes while also offering an access programme to lower patient costs.